Raymond James & Associates Precision Biosciences Inc Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$7.4 - $11.66 $307,810 - $485,009	-41,596 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$9.18 - $14.15 $34,278 - $52,836	-3,734 Reduced 8.24%	41,596 $480,000
Q2 2021 Aug 11, 2021	BUY	$8.07 - $12.52 $365,813 - $567,531	45,330 New	45,330 $568,000
Q4 2020 Feb 12, 2021	SELL	$5.98 - $12.47 $110,354 - $230,121	-18,454 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$4.65 - $8.73 $85,811 - $161,103	18,454 New	18,454 $114,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $744M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.